TargetMol

AD80

Product Code:
 
TAR-T4301
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T4301-1mg1mg£102.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4301-5mg5mg£145.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4301-1mL1 mL * 10 mM (in DMSO)£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4301-10mg10mg£189.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4301-25mg25mg£309.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4301-50mg50mg£462.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4301-100mg100mg£646.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4301-500mg500mg£1,259.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
AD80, a multikinase inhibitor, inhibits RET, RAF, SRCand S6K, with greatly reduced mTOR activity.
CAS:
1384071-99-1
Formula:
C22H19F4N7O
Molecular Weight:
473.436
Pathway:
Tyrosine Kinase/Adaptors; MAPK; PI3K/Akt/mTOR signaling; Apoptosis; Angiogenesis
Purity:
0.999
SMILES:
CC(C)n1nc(-c2ccc(NC(=O)Nc3cc(ccc3F)C(F)(F)F)cc2)c2c(N)ncnc12
Target:
Raf; c-RET; Src; S6 Kinase

References

Dar AC, et al. Chemical genetic discovery of targets and anti-targets for cancer polypharmacology.Nature. 2012 Jun 6;486(7401):80-4. Carlos J A E G, Lima K, Costa-Lotufo L V, et al. AD80, a multikinase inhibitor, exhibits antineoplastic effects in acute leukemia cellular models targeting the PI3K/STMN1 axis[J]. Investigational New Drugs. 2021: 1-11. Carlos J A E G, Lima K, Costa-Lotufo L V, et al. AD80, a multikinase inhibitor, exhibits antineoplastic effects in acute leukemia cellular models targeting the PI3K/STMN1 axis. Investigational New Drugs. 2021 Aug;39(4):1139-1149. doi: 10.1007/s10637-021-01066-w. Epub 2021 Jan 21. Carlos J A E G, Lima K, Costa-Lotufo L V, et al. AD80, a multikinase inhibitor, exhibits antineoplastic effects in acute leukemia cellular models targeting the PI3K/STMN1 axis. Investigational New Drugs. 2021 Aug;39(4):1139-1149. doi: 10.1007/s10637-021-01066-w. Epub 2021 Jan 21. Liu H, et al. Pharmacologic Targeting of S6K1 in PTEN-Deficient Neoplasia.Cell Rep. 2017 Feb 28;18(9):2088-2095. de Almeida L C, Carlos J A E G, Rezende-Teixeira P, et al. AD80, a multikinase inhibitor, as a potential drug candidate for colorectal cancer therapy. Life Sciences. 2022: 120911. Lima K, de Miranda L B L, Del Milagro Bernabe Garnique A, et al.The Multikinase Inhibitor AD80 Induces Mitotic Catastrophe and Autophagy in Pancreatic Cancer Cells.Cancers.2023, 15(15): 3866.